Ultimovacs
Menu Close ✕
  • About
    • About Ultimovacs
    • Team
    • Board of directors
  • Technology
    • Technology overview
    • Immunotherapy
  • Clinical Studies
    • Phase II trials
    • Phase I trials
    • Partnering
    • Expanded access
  • Investors
    • Shares
    • Financial reports
    • Presentations and publications
    • Investor relations contacts
    • Analyst coverage
    • Governance
    • ESG
    • News
  • Contact

Enabling the immune system to fight cancer

Ultimovacs is a biotechcompany developing novel immunotherapies against cancer.

Read more about Ultimovacs Company presentation

Our mission is to extend and improve the life of patients by directing the immune system against the core of cancer.

We will provide universally accessible solutions.

Tweets | @Ultimovacs

See all

Press Releases

Ultimovacs Announces Resignation of Aitana Peire from Board of Directors 28, November, 2023
Ultimovacs ASA: Mandatory notification of trade by primary insider 21, November, 2023
Ultimovacs ASA: New share capital registered 13, November, 2023
Ultimovacs ASA: Share capital increase related to exercise of options 9, November, 2023
Ultimovacs ASA: Mandatory notification of trade by primary insider 8, November, 2023
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update 8, November, 2023
See all

News

Video interview with CEO Carlos de Sousa about the company’s recent top-line data readout for NIPU and its implications for UV1 going forward 14, June, 2023
Interview in MedWatch with CMO Jens Bjørheim regarding the NIPU-trial 14, June, 2023
Biostock Article: About the NIPU study and interview with the Director of Medical Affairs at Ultimovacs, Espen Basmo Ellingsen 6, June, 2023
Ultimovacs Presentation at TD Cowen Healthcare Conference 6, March, 2023
Article published in Current Opinion in Oncology: “Therapeutic cancer vaccination against telomerase” 8, February, 2023
Interview with Professor Gustav Gaudernack (CSO) in BioStock 13, December, 2022
See all

Sign up for company news

E-mail:
mail@ultimovacs.com ir@ultimovacs.com medinfo@ultimovacs.com
Phone number: +47 413 80 080
Ullernchausséen 64
0379 Oslo
Norway View in Google Maps

Technology

  • Technology
  • Clinical studies
  • Immunotherapy

Ultimovacs

  • About Ultimovacs
  • Team
  • Board of directors
  • Contact us

Investors

  • Share information
  • Financial reports
  • Investor relations contacts
  • News
Copyright © Ultimovacs ASA 2023 | Privacy statement